Kiora Pharmaceuticals Announces Exclusive License Agreement With Chong Kun Dang For KIO-301 In South Korea For $1M Upfront, Plus Milestones And Royalties

Loading news article.

Kiora Pharmaceuticals Announces Exclusive License Agreement With Chong Kun Dang For KIO-301 In South Korea For $1M Upfront, Plus Milestones And Royalties | WAPE

Kiora Pharmaceuticals Announces Exclusive License Agreement With Chong Kun Dang For KIO-301 In South Korea For $1M Upfront, Plus Milestones And Royalties

Article summary

Related companies

Analyzed by WAPE AI.

Comments —